Paul Kerr

13 results

Dr Paul Kerr, chief executive Fusion Antibodies. “We are leveraging our antigen expertise to create multiple antigens to be used against the Covid-19 pandemic”

Shares in Northern Ireland pharmaceutical research company Fusion Antibodies soared on Friday after the company said it had developed high-purity anti(...)

Fusion Antibodies said it is positive about the coming 12 months.

Northern Ireland pharmaceutical contract research company Fusion Antibodies said full-year revenues rose almost 80 per cent in the year to the end of (...)

In April, Fusion raised £3m following a share sale. Since then it has generated Covid-19 antigens or molecules capable of stimulating an immune response.   Photograph: iStock

Northern Ireland contract research company Fusion Antibodies said revenues for the year to the end of March will be almost 80 per cent higher than the(...)

Fusion Antibodies will use the funds to expand  its antibody library.

Northern Ireland contract research company Fusion Antibodies has announced a £3 million share placing to expand its mammalian antibody library to incl(...)

Northern Ireland contract research company Fusion Antibodies has so far had a “very limited impact” from the Covid-19 pandemic, with the company remai(...)

Fusion Antibodies is confident of significant revenue growth in the second half of the year

Fusion Antibodies, a pharmaceutical contract research company with its headquarters in Belfast, said revenue continued to grow in the six months to th(...)

Belfast research contract group Fusion Antibodies reported record second-half revenues as it moves past AIM-listing pressures.

Northern Ireland contract research company Fusion Antibodies recorded a 19 per cent fall in full year revenues to £2.2 million on the back of a weak f(...)

Paul Kerr, chief executive of Fusion Antibodies.

Northern Ireland contract research company Fusion Antibodies warned that revenues for the year ended March 31st would be “materially below current mar(...)

Fusion Antibodies CEO Paul Kerr said it had been a challenging period but   company had ‘turned a corner’.

Losses at Belfast pharmaceutical company Fusion Antibodies quadrupled in the six months ended September 30th compared with the same period last year, (...)

Fusion Antibodies has a particular focus on the production of antibodies in a lab. Photograph: iStock

Fusion Antibodies, the Northern Ireland contract research company, has reported losses of nearly £700,000 (€781,000) for its maiden year as an AIM-lis(...)

  • 1
  • 2
  • Next
  • Last »